We're late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw…
Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike's perspective is unique in that he has managed to…
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped…
There is a terrific article in Nature Biotechnology entitled Keys to the Kingdom. The article discusses a number of issues bioentrepreneurs may encounter when trying to license technology from a…
Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by…
Today, Bruce Booth published yet another terrific post, where he discusses the current biotech investment bubble from the private world of venture backed biotechs (and, he puts many mainstream journalists…
There's more to Wyoming than this. In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part…
Is this the next major biotech cluster in the US? Wyoming? Yes, Wyoming. Why not? In the First of a Three-part series, our guest blogger Dr. Garrett Lindemann (@WyomingScience) discusses the…
Our good friend Raman Minhas at ATPBio has a really good post today on the critical factors for a medtech company to be successful using a virtual organizational model. Raman's…